Journal profile · Pharmacology & Pharmacy
Molecular Pharmacology
ISSN 0026-895X · eISSN 1521-0111 · American Society for Pharmacology and Experimental Therapeutics · UNITED STATES · Monthly · Founded 1965
Molecular Pharmacology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.87; hybrid open access; APC about USD 3,600; median 127 days to acceptance (95 articles, last 24 months); community-reported acceptance: fairly hard; 87 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Pharmacology is published by American Society for Pharmacology and Experimental Therapeutics and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Receptor Mechanisms and Signaling, Neuroscience and Neuropharmacology Research and Ion channel regulation and function, together about 37.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Pharmacology Molecular Pharmacology publishes findings derived from the application of innovative structural biology, biochemistry, biophysics, physiology, genetics, and molecular biology to basic pharmacological problems that provide mechanistic insights that are broadly important for the fields of pharmacology and toxicology. Relevant topics include: Molecular Signaling / Mechanism of Drug Action Chemical Biology / Drug Discovery Structure of Drug-Receptor Complex Systems Analysis of Drug Action Drug Transport / Metabolism ASPET The American Society for Pharmacology and Experimental Therapeutics (ASPET) is a 4,000 member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, large pharmaceutical companies, small biotech companies, and non-profit organizations. ASPET members work in a variety of different fields and include neuroscientists, toxicologists, chemical biologists, pharmacists, cardiovascular scientists, and many more. Though very diverse, our members have a common bond through their membership in ASPET. Our members' research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases. More Opens in new window
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief John TesmerPublisher website
Editorial board by country: 1 in mainland China (about 1%); most named United States 75, Germany 7, United Kingdom 5, India 3, Sweden 2 (102 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology17.9%
- Neuroscience and Neuropharmacology ResearchNeuroscience11%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology8.5%
- Neuropeptides and Animal PhysiologyNeuroscience7.1%
- Nicotinic Acetylcholine Receptors StudyBiochemistry, Genetics and Molecular Biology4.6%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.4%
- Drug Transport and Resistance MechanismsMedicine4.1%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.87LetPub ·
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 5.2LetPub ·
- CiteScore (publisher)
- 5.2Publisher website ·
- SJR 2026-06
- 1.15LetPub ·
- SNIP 2026-06
- 0.87LetPub ·
- h-index
- 186LetPub ·
- h-index
- 276OpenAlex ·
- i10-index
- 10,821OpenAlex ·
- 2-year mean citedness
- 3.5OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 26.15%LetPub ·
Volume
- Articles per year
- 111LetPub ·
Articles by year OpenAlex count · 14,782 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 54 | 34 | 13 |
| 2025 | 87 | 62 | 175 |
| 2024 | 89 | 59 | 617 |
| 2023 | 82 | 47 | 505 |
| 2022 | 88 | 58 | 713 |
| 2021 | 124 | 97 | 1,574 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
127 daysMedian, submission to acceptance · P25–P75 88 days – 158 days
- Acceptance to online
- median 7 days (95 articles)
- Submission to online
- median 133 days
- Sample
- 95 articles with submission and acceptance dates (164 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,600 / EUR 3,370 / GBP 2,880 / JPY 446,510 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Society for Pharmacology and Experimental Therapeutics
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1965
- ISSN
- 0026-895X
- Electronic ISSN
- 1521-0111
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Molecular Pharmacology
What CAS zone is Molecular Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Pharmacology is in Zone 4 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Pharmacology?
The latest impact factor listed by LetPub is 2.87; CiteScore 5.2, h-index 276.
How long does peer review take at Molecular Pharmacology?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 127 days (interquartile range 88–158 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Molecular Pharmacology based?
Of the 102 board members whose country the journal's board page names, 1 (about 1%) are in mainland China; the countries named most often are United States (75), Germany (7) and United Kingdom (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Pharmacology?
According to LetPub and DOAJ records, Molecular Pharmacology is indexed in SCIE and Scopus.
Is Molecular Pharmacology open access, and what is the APC?
Molecular Pharmacology is a hybrid journal. For open-access publication: APC about USD 3,600.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .